Hemostemix Inc. (HEM.V)
| Previous Close | 0.1700 |
| Open | 0.1700 |
| Bid | 0.1550 x 0 |
| Ask | 0.1600 x 0 |
| Day's Range | 0.1500 - 0.1700 |
| 52 Week Range | 0.1300 - 0.4200 |
| Volume | |
| Avg. Volume | 104,446 |
| Market Cap | 12.119M |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1230 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.96 |
- Newsfile
Hemostemix Announces Exploring Clinical Trial Financing Alternatives
Calgary, Alberta--(Newsfile Corp. - October 4, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that the Company has commenced discussions with pharmaceutical companies to explore potential clinical trial financing alternatives for its lead product ACP-01 (the "Clinical Trial Financing Alternatives"), after retaining experts in the field of biotech business development who have significant experience completing deals on behalf
- Newsfile
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 27, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to its Scientific Advisory Board.Dr. von Schwarz is a US based world renowned, triple board certified clinical and academic cardiologist and clinical professor of medicine at UCLA and UC Riverside. He joined Cedars Sinai Medical Center and UCLA ...
- Newsfile
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
Calgary, Alberta--(Newsfile Corp. - September 20, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Terry Hébert, PhD, to its Scientific Advisory Board.Dr. Hébert is the Assistant Dean for Biomedical Science Education in the Faculty of Medicine and Health Sciences at McGill University, the Director of the McGill Regenerative Medicine Network, and a Professor in the Department of Pharmacology and Therapeuti
